Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 2/20 | 0.43 |
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21841471 | 1.00 | NOS1 (0.43) | NOS1NOS3NOS2CA12CA14 | |
| SCHEMBL19981342 | 1.00 | NOS1 (0.43) | NOS1NOS3NOS2CA12CA14 | |
| SCHEMBL21841469 | 1.00 | NOS1 (0.43) | NOS1NOS3NOS2CA12CA14 | |
| SCHEMBL918458 | 1.00 | NOS1 (0.43) | NOS1NOS3NOS2CA12CA14 | |
| Hydrochloric Acid SCHEMBL2405478 | 0.98 | NOS1 (0.42) | NOS1NOS3NOS2CA12CA14 | |
| Hydrochloric Acid SCHEMBL2405476 | 0.98 | NOS1 (0.42) | NOS1NOS3NOS2CA12CA14 | |
| Acetic Acid SCHEMBL12615515 | 0.94 | NOS1 (0.40) | NOS1NOS3NOS2SLC7A5 | |
| Acetic Acid SCHEMBL29787814 | 0.94 | NOS1 (0.40) | NOS1NOS3NOS2SLC7A5 | |
| Acetic Acid SCHEMBL12615511 | 0.94 | NOS1 (0.40) | NOS1NOS3NOS2SLC7A5 | |
| SCHEMBL7367529 | 0.85 | NOS1 (0.33) | NOS1NOS3NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116675736-A | Synthetic method of polypeptide growth factor PSK | 杭州东恒生物医药有限公司 | 2023-09-01 | — | — | CN | claimed |
| CN-110790674-A | Method for continuously producing O-tert-butyl-L-threonine tert-butyl ester | 熊飞龙 | 2020-02-14 | — | — | CN | claimed |
| CN-110790673-A | Method for preparing O-tert-butyl-L-threonine tert-butyl ester | 熊飞龙 | 2020-02-14 | — | — | CN | claimed |
| US-20080108787-A1 | Purification of Insulin-Like Material by Reverse Phase Chromatography | WOCKHARDT LIMITED (IN) | 2008-05-08 | — | — | US | claimed |
| EP-1758540-A4 | PURIFICATION OF INSULIN-LIKE MATERIAL BY REVERSE PHASE CHROMATOGRAPHY | WOCKHARDT LTD (IN) | 2007-06-20 | — | — | EP | claimed |
| EP-1758540-A1 | PURIFICATION OF INSULIN-LIKE MATERIAL BY REVERSE PHASE CHROMATOGRAPHY | Wockhardt Limited (IN) | 2007-03-07 | — | — | EP | claimed |
| WO-2005115303-A1 | PURIFICATION OF INSULIN-LIKE MATERIAL BY REVERSE PHASE CHROMATOGRAPHY | WOCKHARDT LIMITED (IN) | 2005-12-08 | — | — | WO | claimed |
| EP-4733307-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND USING MIXED ANHYDRIDE PROCEDURE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-04-29 | — | — | EP | disclosed |
| EP-4306530-B1 | SILANE-CONTAINING CONDENSED CYCLIC DIPEPTIDE COMPOUND, PRODUCTION METHOD THEREFOR, AND METHOD FOR PRODUCING POLYPEPTIDE COMPOUND USING SAME | CHUBU UNIV EDUCATIONAL FOUNDATION (JP) | 2026-04-01 | — | — | EP | disclosed |
| US-20260022102-A1 | 1,2,4-Oxadiazole and Thiadiazole Compounds as Immunomodulators | AURIGENE ONCOLOGY LIMITED (IN) | 2026-01-22 | — | — | US | disclosed |
| EP-4538279-A2 | REACTION AGENT FOR AMIDE REACTIONS AND AMIDE COMPOUND PRODUCTION METHOD USING SAME | Chubu University Educational Foundation (JP) | 2025-04-16 | — | — | EP | disclosed |
| WO-2025070753-A1 | METHOD FOR PRODUCING PEPTIDE COMPOUND USING MIXED ANHYDRIDE PROCEDURE | 中外製薬株式会社 | 2025-04-03 | — | — | WO | disclosed |
| CN-119591674-A | Cyclohexapeptide and preparation method and application thereof | 陕西未来多肽生物科技有限公司 | 2025-03-11 | — | — | CN | disclosed |
| US-4154946-A | Amino mercapto substituted acylamino acids | E. R. SQUIBB & SONS, INC. (US) | 1979-05-15 | — | — | US | disclosed |
| US-4146611-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1979-03-27 | — | — | US | disclosed |
| US-4129571-A | Amino acid derivatives | E. R. SQUIBB & SONS, INC. (US) | 1978-12-12 | — | — | US | disclosed |
| US-4128721-A | Amino acid derivatives | E. R. SQUIBB & SONS, INC. (US) | 1978-12-05 | — | — | US | disclosed |
| US-4127729-A | Amino acid derivatives | E. R. SQUIBB & SONS, INC. (US) | 1978-11-28 | — | — | US | disclosed |
| US-4113715-A | Amino acid derivatives | E. R. SQUIBB & SONS, INC. (US) | 1978-09-12 | — | — | US | disclosed |
| US-4091024-A | Pyrrolidine and piperidine-2-carboxylic acid derivatives | E. R. SQUIBB & SONS, INC. (US) | 1978-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022102-A1 | 1,2,4-Oxadiazole and Thiadiazole Compounds as Immunomodulators | CD274, PDCD1, PDCD1LG2 | NOS1 1425/4885NOS3 1541/4885NOS2 2099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.